Latest Tax Incentives News

Aeeris Ltd has reported a profitable second quarter for FY26, with total unadjusted revenue rising 61% year-on-year to $1.54 million and annual recurring revenue climbing 16.5% to nearly $4 million. The company’s operational advances and disciplined cost control underpin a promising path to sustainable profitability.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Australian Vanadium Limited has made significant strides in its integrated vanadium project, advancing its feasibility study and securing key environmental approvals while preparing to bid for a major Western Australian battery storage project.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Strategic Elements Ltd reports steady progress in its cutting-edge ventures across automation, AI, and material science, supported by a strong cash position and government-backed innovation incentives.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

Argenica Therapeutics has unveiled compelling AI-driven results confirming ARG-007’s significant benefits in severe acute ischemic stroke patients, setting the stage for a precision-focused Phase 2b trial.

Environmental Clean Technologies Limited has completed the acquisition of Terrajoule, gaining exclusive rights to a cutting-edge soil remediation technology targeting PFAS contamination. The company also bolstered its leadership and funding to accelerate commercialisation.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

Elixir Energy has commenced drilling at the Lorelle-3 appraisal well in Queensland’s Taroom Trough, targeting significant gas resources with plans for advanced testing by mid-2026.